Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

November 11, 2024

Study Completion Date

December 31, 2025

Conditions
NETs
Interventions
DRUG

68Ga-DOTATATE Injection

The eligible subjects who participate in 68Ga study will be intravenously injected with 68Ga-DOTATATE Injection on Day1,and undergo PET/CT examination within 60 minutes after injection. Corresponding safety examination is performed before administration of 68Ga-DOTATATE Injection, 3h±1.0h after administration, and Day2. Telephone safety visit is conducted at Day7 after administration.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

HTA Co., Ltd.

INDUSTRY

NCT07119242 - Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs | Biotech Hunter | Biotech Hunter